Abstract
Surfactants are important ingredients in pharmaceutical and cosmetic formulations, as in creams, shampoos or shower gels. As conventional emulsifiers such as sodium dodecyl sulfate (SDS) have fallen into disrepute due to their skin irritation potential, the naturally occurring lecithins are being investigated as a potential alternative. Thus, lecithin-based nanoemulsions with and without the drug curcumin, known for its wound healing properties, were produced and characterised in terms of their particle size, polydispersity index (PDI) and zeta potential and compared to SDS-based formulations. In vitro toxicity of the produced blank nanoemulsions was assessed with primary human keratinocytes and fibroblasts using two different cell viability assays (BrdU and EZ4U). Further, we investigated the penetration profiles of the deployed surfactants and oil components using combined ATR-FTIR/tape stripping experiments and confirmed the ability of the lecithin-based nanoemulsions to deliver curcumin into the stratum corneum in tape stripping-UV/Vis experiments.
All manufactured nanoemulsions showed droplet sizes under 250 nm with satisfying PDI and zeta potential values. Viability assays with human skin cells clearly indicated that lecithin-based nanoemulsions were superior to SDS-based formulations. ATR-FTIR tests showed that lecithin and oil components remained in the superficial layers of the stratum corneum, suggesting a low risk for skin irritation. Ex vivo tape stripping experiments revealed that the kind of oil used in the nanoemulsion seemed to influence the depth of curcumin penetration into the stratum corneum.
Titel in Übersetzung | Effekt von Lezithin-basierten Nanoemulsionen auf Haut: Kurzzeitige MTT und BrdU - Zytotoxizitätstests, Hautpenetration von Tensiden, weiteren Hilfsstoffen und Curcumin |
---|---|
Originalsprache | Englisch |
Aufsatznummer | 119209 |
Seitenumfang | 10 |
Fachzeitschrift | International Journal of Pharmaceutics |
Jahrgang | 580 |
DOIs | |
Publikationsstatus | Veröffentlicht - 30 Apr. 2020 |
ÖFOS 2012
- 301208 Pharmazeutische Technologie